CDER Conversations
CDER Conversation: CDER Creates New Biosimilars Resources for Educators, Teaching Facilities
FDA’s Center for Drug Evaluation and Research’s Office of Therapeutic Biologics and Biosimilars (OTBB) released its first-ever curriculum toolkit for educators to help students in health care professional degree programs improve their understanding of biosimilar and interchangeable biosimilar biological products and their regulatory approval pathway in the U.S.
Sarah Yim, M.D., OTBB director, explains the new educational toolkit and its importance to medicine, nursing, and pharmacy students as well as educators.